PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to poor response rates to conventional treatments. In the era of precision medicine, the improved understanding of cancer genetics and molecular biology has led to the development of targeted therapies, such as pol...

Descripción completa

Detalles Bibliográficos
Autores principales: Musacchio, Lucia, Caruso, Giuseppe, Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Attademo, Laura, Tambaro, Rosa, Russo, Daniela, Califano, Daniela, Palaia, Innocenza, Muzii, Ludovico, Benedetti Panici, Pierluigi, Pignata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383016/
https://www.ncbi.nlm.nih.gov/pubmed/32801862
http://dx.doi.org/10.2147/CMAR.S221001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383016/
https://www.ncbi.nlm.nih.gov/pubmed/32801862
http://dx.doi.org/10.2147/CMAR.S221001

Ejemplares similares